Credit Suisse Reiterates Underperform on Cochlear (COH)
Cochlear (ASX: COH)‘s stock had its “underperform” rating restated by equities researchers at Credit Suisse in a report issued on Wednesday. They currently have a $80.00 (76 AUD) target price on the stock.
Cochlear remained flat at A$80.000 during trading on Wednesday. Cochlear has a 52-week low of A$51.310 and a 52-week high of A$71.790. The stock’s 50-day moving average is currently A$68.1. The company has a market cap of A$4.549 billion and a price-to-earnings ratio of 80.16.
COH has been the subject of a number of other recent research reports. Analysts at Macquarie reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Friday, November 23rd. They now have a $71.35 price target on the stock. Separately, analysts at Goldman Sachs reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Monday, November 12th. They now have a $67.71 price target on the stock. Finally, analysts at Nomura reiterated a “neutral” rating on shares of Cochlear in a research note to investors on Tuesday, October 30th. They now have a $70.31 price target on the stock.
Cochlear Limited (Cochlear) is an Australia-based company, which operates in the implantable hearing device industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

If the aud drops somewhat against foreign currencies through the year as many are suggesting will eventually happen, then they will have to up their price estimates.